Literature DB >> 17942895

RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors.

Richard W Martin1, Brian J Orelli, Mitsuyoshi Yamazoe, Andy J Minn, Shunichi Takeda, Douglas K Bishop.   

Abstract

The breast cancer susceptibility gene BRCA1 encodes a large protein thought to contribute to a variety of cellular processes, although the critical determinants of BRCA1-deficient tumorigenesis remain unclear. Given that BRCA1 is required for cell proliferation, suppressor mutations are believed to modify BRCA1 phenotypes and contribute to the etiology of BRCA1-deficient tumors. Here, we show that overexpression of the homologous recombinase RAD51 in a DT40 BRCA1Delta/Delta mutant rescues defects in proliferation, DNA damage survival, and homologous recombination (HR). In addition, epistasis analysis with BRCA1 and the DNA end-joining factor KU70 indicates that these factors operate independently of one another to repair double-strand breaks. Consistent with this genetic finding, cell synchronization studies show that the ability of BRCA1 to promote radioresistance is restricted to the late S and G2 phases of the cell cycle, as predicted for genes whose function is specific to homology-mediated repair rather than nonhomologous end-joining. Notably, retrospective analyses of microarray expression data reveal elevated expression of RAD51 and two of its late-acting cofactors, RAD54 and RAD51AP1, in BRCA1-deficient versus sporadic breast tumors. Taken together, our results indicate that up-regulation of HR provides a permissive genetic context for cells lacking BRCA1 function by circumventing its requirement in RAD51 subnuclear assembly. Furthermore, the data support a model in which enhanced HR activity contributes to the etiology of BRCA1-deficient tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17942895     DOI: 10.1158/0008-5472.CAN-07-0290

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  83 in total

1.  Genomic instability in chronic myeloid leukemia: targets for therapy?

Authors:  N Muvarak; P Nagaria; F V Rassool
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

2.  The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.

Authors:  Xiaozhe Wang; David T Weaver
Journal:  Am J Cancer Res       Date:  2010-01-03       Impact factor: 6.166

3.  High levels of RAD51 perturb DNA replication elongation and cause unscheduled origin firing due to impaired CHK1 activation.

Authors:  Ann Christin Parplys; Jasna Irena Seelbach; Saskia Becker; Matthias Behr; Agnieszka Wrona; Camilla Jend; Wael Yassin Mansour; Simon Andreas Joosse; Horst-Werner Stuerzbecher; Helmut Pospiech; Cordula Petersen; Ekkehard Dikomey; Kerstin Borgmann
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 4.  The consequences of Rad51 overexpression for normal and tumor cells.

Authors:  Hannah L Klein
Journal:  DNA Repair (Amst)       Date:  2008-02-01

5.  ZNF365 promotes stalled replication forks recovery to maintain genome stability.

Authors:  Yuqing Zhang; Eunmi Park; Christopher S Kim; Ji-hye Paik
Journal:  Cell Cycle       Date:  2013-08-06       Impact factor: 4.534

6.  Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.

Authors:  Christian Bowman-Colin; Bing Xia; Samuel Bunting; Christiaan Klijn; Rinske Drost; Peter Bouwman; Laura Fineman; Xixi Chen; Aedin C Culhane; Hong Cai; Scott J Rodig; Roderick T Bronson; Jos Jonkers; Andre Nussenzweig; Chryssa Kanellopoulou; David M Livingston
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-08       Impact factor: 11.205

7.  DNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells.

Authors:  Zhiyong Mao; Ying Jiang; Xiang Liu; Andrei Seluanov; Vera Gorbunova
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

8.  The RAD51-stimulatory compound RS-1 can exploit the RAD51 overexpression that exists in cancer cells and tumors.

Authors:  Jennifer M Mason; Hillary L Logan; Brian Budke; Megan Wu; Michal Pawlowski; Ralph R Weichselbaum; Alan P Kozikowski; Douglas K Bishop; Philip P Connell
Journal:  Cancer Res       Date:  2014-04-21       Impact factor: 12.701

9.  Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins.

Authors:  Hideki Asakawa; Hirotaka Koizumi; Ayaka Koike; Makiko Takahashi; Wenwen Wu; Hirotaka Iwase; Mamoru Fukuda; Tomohiko Ohta
Journal:  Breast Cancer Res       Date:  2010-03-05       Impact factor: 6.466

10.  MDC1 and RNF8 function in a pathway that directs BRCA1-dependent localization of PALB2 required for homologous recombination.

Authors:  Fan Zhang; Gregory Bick; Jung-Young Park; Paul R Andreassen
Journal:  J Cell Sci       Date:  2012-10-04       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.